Andrew Roberts is Chief Portfolio Officer at Alvotech. He leads the portfolio strategy, including several enterprise leaderships functions responsible for the successful registration and partner commercialization of our biosimilars.
Andrew comes to Alvotech with over 15 years of experience in both originator and biosimilar strategy and development. Most recently, he led development portfolio strategy and several key collaborations for Sandoz's biosimilar portfolio. Prior to this Andrew led originator development teams in a variety of therapeutic areas within Novartis and has also worked on portfolio strategy at the group level for the Board of Directors.
Andrew holds an Executive MBA from INSEAD and an MS in Nutrition and a BS in Biology from Louisiana State University.